Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET

Company Participants

Jennifer Viera - Investor Relations
Jay Luly - President and Chief Executive Officer
Paul Mellett - Chief Financial Officer
Scott Rottinghaus - Chief Medical Officer
Tara Kieffer - Chief Product Strategy Officer

Conference Call Participants

Eric Joseph - JPMorgan
Roy Buchanan - Citizens JMP
Nik Gasic - Leerink Partners
Jay Olson - Oppenheimer

Operator

Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal Second Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode. There will be a question-and-answer session at the end of the prepared remarks. Please be advised that this call is being recorded.

I would now like to turn the call over to Jennifer Viera, Investor Relations. Please go ahead.

Jennifer Viera

Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal second quarter financial results was issued this afternoon and is available on our website.

Making remarks on today's call are Dr. Jay Luly, President and Chief Executive Officer; and Paul Mellett, our Chief Financial Officer. Dr. Scott Rottinghaus, our Chief Medical Officer; and Dr. Tara Kieffer, our Chief Product Strategy Officer will be available during the Q&A portion of this call.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements. These statements may include our plans and expectations with respect to our research and development pipeline and financial projections. All of these statements involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent Form 10-K, and our other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call.

I'd now like to turn the call over to Dr. Jay Luly, President and CEO. Jay?

Jay Luly

Thank you, Jennifer, and good afternoon, everyone. Throughout 2024, Enanta has remained squarely focused on advancing our virology and immunology pipeline to bring important oral therapeutics to market. Our commitment to developing treatments for areas of high unmet need is driven by our mission to transform patients' lives with curative therapies and we are determined to achieve our milestones to drive near and long-term shareholder value to fulfill this mission. Our focus is critical as we approach meaningful inflection points with the potential to develop the first anti-viral treatment for RSV.